<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Piccand, Matthieu</dc:creator>
  <dc:creator>Bessa, Juliana</dc:creator>
  <dc:creator>Schick, Eginhard</dc:creator>
  <dc:creator>Senn, Claudia</dc:creator>
  <dc:creator>Bourquin, Carole</dc:creator>
  <dc:creator>Richter, Wolfgang F.</dc:creator>
  <dc:date>2015-11-24</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The purpose of this study is to test the feasibility of neonatal immune tolerance  induction in mice to enable long-term pharmacokinetic studies with immunogenic  therapeutic monoclonal antibodies (mAb). Neonatal immune tolerance was induced by  transfer of a mAb to neonatal mice via colostrum from nursing mother mice treated with  two subcutaneous doses of a tolerogen starting within the first 24 h after delivery.  Adalimumab and efalizumab were administered as tolerogens at various dose levels.  Tolerance induction was evaluated in the offspring after reaching adulthood at 8 weeks  of age. After a single intravenous injection of the same mAb as used for tolerance  induction, the pharmacokinetics of the mAb and formation of anti-drug antibodies (ADA)  in plasma were assessed using ELISA. Tolerance induction to adalimumab was  achieved in a maternal dose-dependent manner. Adalimumab immune-tolerant  offspring showed a slower adalimumab clearance (4.24 ± 0.32 mL/day/kg) as  compared to the control group (12.09 ± 3.81 mL/day/kg). In the control group,  accelerated clearance started 7 days after adalimumab dosing, whereas immune- tolerant offspring showed a log-linear terminal concentration-time course. In the  offspring, the absence of predose ADA levels was indicative of successful tolerance  induction. The second test compound efalizumab was not immunogenic in mice under  our experimental conditions. Overall, the present study demonstrated the suitability of  neonatal immune tolerance induction for a 4-week single dose study in adult mice with  a human therapeutic mAb that is otherwise immunogenic in laboratory animals.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/304977</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/304977/files/bou_nit.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1208/s12248-015-9850-5</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>The AAPS Journal. - 2016, vol. 18, no. 2, p. 354–361</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Neonatal immune tolerance induction to allow long-term studies with an immunogenic therapeutic monoclonal antibody in mice</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
